Pravastatin inhibits tumor growth through elevating the levels of apolipoprotein A1

Conclusion This study demonstrated that pravastatin elevated ApoA1, an HDL major constituent with anti-inflammatory characteristics, which displayed strong adversary associations with tumor developments and growth. Increasing the amounts of ApoA1 by pravastatin coupled with DOX may improve the therapeutic efficacy for cancer treatment.
Source: Advances in Digestive Medicine - Category: Gastroenterology Source Type: research